Overview

Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD

Status:
Terminated
Trial end date:
2020-05-15
Target enrollment:
Participant gender:
Summary
The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction of Peripheral Arterial Occlusive Disease-related clinically relevant ulcers) and safety (by monitoring adverse events) of one dose of allo-APZ2-PAOD administered intramuscularly into an affected lower leg of patients with Peripheral Arterial Occlusive Disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
RHEACELL GmbH & Co. KG
Collaborators:
FGK Clinical Research GmbH
Granzer Regulatory Consulting & Services
Ticeba GmbH